(Total Views: 282)
Posted On: 03/14/2022 7:13:44 PM
Post# of 1418
Re: StoneBridge54 #575
The link was in my response to you at the bottom.
Since these questions will keep coming up, here a FAQ that took me 2 minutes to type
Todos Investor FAQ
Q: When are earnings announced?
A: 45 days after quarter closed. Q4 and EOY announced 90 days. March 31st or before.
Q: Is there going to be a reverse split soon and at these levels?
A: No
Q: Does Todos present at investor conferences?
A: Yes, the next one is March 17, 2022 at Proactive
https://event.webinarjam.com/register/1496/vyy7gs78o
Q: Are earnings announced at investor conferences?
A: Usually not. Usually there is a separate call for investors and analysts.
Q: When is the deal with NCL Pharma closing?
A: It closed March 10, 2022
Q: When will the deal with NCL Pharma be announced and what is the new company name?
A: Likely this week and the new company will be 3CL Pharma
Q: Is Todos getting 60% of 3CL Pharma for free?
A: No
Q: What is the terms of the 3CL Phama deal?
A: You'll know when the PR comes and the SEC filing?
Since these questions will keep coming up, here a FAQ that took me 2 minutes to type
Todos Investor FAQ
Q: When are earnings announced?
A: 45 days after quarter closed. Q4 and EOY announced 90 days. March 31st or before.
Q: Is there going to be a reverse split soon and at these levels?
A: No
Q: Does Todos present at investor conferences?
A: Yes, the next one is March 17, 2022 at Proactive
https://event.webinarjam.com/register/1496/vyy7gs78o
Q: Are earnings announced at investor conferences?
A: Usually not. Usually there is a separate call for investors and analysts.
Q: When is the deal with NCL Pharma closing?
A: It closed March 10, 2022
Q: When will the deal with NCL Pharma be announced and what is the new company name?
A: Likely this week and the new company will be 3CL Pharma
Q: Is Todos getting 60% of 3CL Pharma for free?
A: No
Q: What is the terms of the 3CL Phama deal?
A: You'll know when the PR comes and the SEC filing?
(1)
(0)
Scroll down for more posts ▼